JFP-- In my previous post, I said bipl was in buy range, and after reading this news, I am glad I have been buying it for the past few days.
>>>>>>>>Thursday July 10 6:31 AM EDT
Company Press Release
Biopool International Receives Approval To Sell Products
in Japan
VENTURA, Calif.--(BUSINESS WIRE)--July 10, 1997--Biopool International Inc.
(NASDAQ:BIPL) Thursday announced that the company has received the Japanese Ministry of
Health's approval to market four additional products in Japan.
The four products are monoclonal antibody-based reagents for use in blood grouping and typing
and in cross-matching for blood transfusions. These reagents are a part of the immunohematology
product range of the recently acquired BCA division of Biopool and supplement approximately 50
other Biopool products already approved for sale in Japan.
Further, Biopool Thursday announced that the company has appointed Cosmo Bio to distribute its
new immunohematology product line in Japan. Cosmo Bio has been the distributor for Biopool's
hemostasis product line in Japan for the past 7 years.
Michael D. Bick, Ph.D., chairman and chief executive officer of Biopool, stated: ``These four
newly approved monoclonals are the most commonly used reagents in blood bank facilities
worldwide. Cosmo Bio has not had access to this market segment in the past, and we are
confident that the availability of these core reagents will allow Cosmo Bio to grow this business in
Japan. Biopool has had a long-standing relationship with Cosmo Bio, and we look forward to
expanding our business in Japan for both hemostasis and immunohematology products.''
Cosmo Bio Co. Ltd. was founded in 1983 as a part of Cosmo Oil and is active in the distribution
of biochemical reagents and clinical diagnostic products.
Founded in 1987, Biopool International develops, manufactures and markets a full range of test
kits to assess and diagnose disorders of blood coagulation, thrombotic risk factors, fibrinolysis,
platelet function and the vascular system; specialty chemistry controls used to monitor and measure
the presence of drugs of abuse; and blood group serology products used to screen for antibodies
and group and type whole blood.
The company's product line of more than 150 FDA-approved products are sold to hospitals,
blood bank facilities and clinical and reference laboratories on a worldwide basis through an
extensive network of distributors.
Contact:
Biopool International Inc., Ventura
Michael D. Bick or Carol Hill, 805/654-0643 |
